Ghana introduces clinical trials framework
This article was originally published in SRA
Executive Summary
The Council for Scientific and Industrial Research in the African nation of Ghana has set up its first institutional review board to have oversight over clinical trials performed in the country. An institutional animal care and use committee has also been established to protect the welfare of animals used in research1,2.
You may also be interested in...
Asian patient recruitment comes of age
Asia has been rapidly developing in importance as a destination for global clinical trials in recent years. The recent launch of a major new report by the European Medicines Agency (EMA) shows that the region is still growing strongly as a site for patient recruitment. Still, there is, as always, wide variability by country and the region has not remained static, with at least one country that was previously a cornerstone of growth seeing recruitment decline in the face of ongoing quality issues, while another formerly isolated nation is rapidly becoming a key destination for global trials.
Cetero appoints new director of quality and compliance
The early-phase US-based clinical contract research organisation Cetero Research has appointed James Dixon to be its senior vice president of quality and compliance. Mr Dixon joins the Cary, North Carolina-based firm from Medimmune, where he held the position of vice president of GxP Quality Compliance. Mr Dixon's 25-year long career in the pharmaceutical industry has seen him hold executive positions at a number of CROs, including Parexel International, ClinTrials Research, and Covance.
Critical Path Institute seeks new leader as founder retires
The founder of the Arizona-based Critical Path Institute (C-Path), Raymond Woosley, has announced that he is to retire on 31 January 2012, leaving its board of directors in search of a new chief executive1. Woosley founded C-Path six years ago as a non-profit organisation fostering partnerships between pharmaceutical firms and regulatory bodies, increasing the speed and efficiency of drug development, to get novel drugs to patients more quickly2. While retiring from running its day-to-day operations, he will remain involved with the firm and retain his seat on the board.